Venlafaxine (Effexor) and CYP2D6 Pharmacogenomics
Last updated: February 2026
What Is Venlafaxine?
Venlafaxine (brand name Effexor, Effexor XR) is a serotonin-norepinephrine reuptake inhibitor (SNRI) prescribed for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It is one of the most commonly prescribed antidepressants.
What makes venlafaxine relevant to pharmacogenomics is that the CYP2D6 enzyme is the primary enzyme responsible for converting venlafaxine to its active metabolite, O-desmethylvenlafaxine (desvenlafaxine). Importantly, both the parent drug and the metabolite are pharmacologically active — making the pharmacogenomic picture more nuanced than for drugs with inactive metabolites.
How CYP2D6 Affects Venlafaxine Metabolism
After oral administration, venlafaxine is metabolized primarily by CYP2D6 through O-demethylation to produce desvenlafaxine. This metabolite is itself an FDA-approved antidepressant (marketed separately as Pristiq) and has equivalent pharmacological activity to the parent compound.
Your CYP2D6 metabolizer status affects the ratio of venlafaxine to desvenlafaxine, but because both are active, the total pharmacological exposure (active moiety) remains relatively similar across CYP2D6 phenotypes. This is a key difference from drugs like codeine, where the metabolite (morphine) is the primary source of therapeutic effect.
CYP2D6 poor metabolizers have higher venlafaxine levels and lower desvenlafaxine levels, while ultrarapid metabolizers have the reverse pattern. The clinical significance of this altered ratio — as opposed to altered total exposure — is less clear, which is reflected in CPIC's more nuanced recommendations for venlafaxine compared to other CYP2D6-dependent medications. Learn more about how pharmacogenomic testing works from raw DNA data.
Have 23andMe or AncestryDNA raw data? Find out if venlafaxine is flagged for your CYP2D6 genotype.
Impact of CYP2D6 Metabolizer Status
Your CYP2D6 phenotype affects the venlafaxine-to-desvenlafaxine ratio:
- Ultrarapid Metabolizer (UM): Increased CYP2D6 activity leads to more rapid conversion to desvenlafaxine. Venlafaxine levels are lower, desvenlafaxine levels are higher. Total active moiety may be reduced. Some patients may experience subtherapeutic effects; monitoring is reasonable.
- Normal Metabolizer (NM): Standard CYP2D6 function. Typical venlafaxine-to-desvenlafaxine ratio. Standard dosing applies.
- Intermediate Metabolizer (IM): Moderately reduced CYP2D6 activity. Higher venlafaxine and lower desvenlafaxine levels compared to normal metabolizers. Total active moiety remains similar. No specific dose adjustment typically needed.
- Poor Metabolizer (PM): Significantly reduced CYP2D6 activity. Substantially higher venlafaxine levels with lower desvenlafaxine levels. Total active moiety exposure is relatively preserved. Side effects may differ in profile (more serotonergic relative to noradrenergic). CPIC notes monitoring may be warranted but does not recommend a specific dose change based on genotype alone.
For a plain-language explanation of metabolizer categories, read our guide to metabolizer status.
CPIC Guideline Summary
The venlafaxine–CYP2D6 interaction has CPIC guideline coverage. Because both venlafaxine and desvenlafaxine are active, CPIC takes a more measured approach than for drugs with inactive metabolites:
- NM: Initiate therapy at standard dose per prescribing information.
- IM: No specific dose adjustment. Standard dosing with monitoring.
- PM: No specific dose adjustment recommended by CPIC based on genotype alone. Monitor for side effects. The altered venlafaxine-to-desvenlafaxine ratio may affect the side-effect profile. All treatment decisions remain with the prescriber.
- UM: Monitor for reduced effectiveness. Consider titrating or selecting an alternative if response is inadequate. Prescriber discretion.
This is notably different from CYP2D6 recommendations for drugs like paroxetine or atomoxetine, where CYP2D6 status has a more direct impact on total drug exposure. Understanding this distinction helps contextualize your results.
Already have your DNA file? Check whether your CYP2D6 status affects venlafaxine metabolism.
Learn how to upload your data · About the Psychiatric Medication Report
Understanding Your Results
If you have raw DNA data from 23andMe, AncestryDNA, or another consumer service, DecodeMyBio can analyze your CYP2D6 status and report whether venlafaxine is flagged for your genotype. Your Psychiatric Medication Report will include your CYP2D6 diplotype, activity score, metabolizer phenotype, and the CPIC context for venlafaxine specifically.
Venlafaxine response depends on factors beyond CYP2D6, including other medications, renal function (desvenlafaxine is renally cleared), age, and clinical indication. See our methodology for how results are derived and our limitations page for important caveats.
Related Resources
Frequently Asked Questions
Why does CYP2D6 matter for venlafaxine?
CYP2D6 converts venlafaxine to its active metabolite desvenlafaxine. Your CYP2D6 status affects the ratio between the two, though total active moiety exposure remains relatively similar across phenotypes.
What does CPIC recommend for CYP2D6 poor metabolizers taking venlafaxine?
CPIC does not recommend a specific dose change based on CYP2D6 status alone because total active moiety exposure is relatively preserved. Monitoring for side effects may be warranted. Treatment decisions remain with the prescriber.
Is venlafaxine an SSRI or SNRI?
Venlafaxine is an SNRI — it inhibits both serotonin and norepinephrine reuptake. This differs from SSRIs like escitalopram and sertraline, which primarily affect serotonin. The pharmacogenomics also differ: venlafaxine is CYP2D6-dependent, while most SSRIs are CYP2C19-dependent.
Does CYP2D6 status affect desvenlafaxine (Pristiq)?
Desvenlafaxine is the active metabolite of venlafaxine and is itself renally cleared, not CYP2D6-dependent. If prescribed desvenlafaxine directly, CYP2D6 status is less clinically relevant.
Can 23andMe raw data show my CYP2D6 status for venlafaxine?
Yes. Consumer arrays include many CYP2D6 SNP variants. However, gene deletions and duplications cannot be detected, which may affect some phenotype classifications.
Does venlafaxine pharmacogenomics predict if the drug will work for my depression or anxiety?
No. Pharmacogenomics shows how your body metabolizes venlafaxine — not whether it will be effective for your condition. Treatment response depends on many factors beyond drug metabolism.
Last reviewed: February 2026 · DecodeMyBio Editorial Team